{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:14:44Z","timestamp":1762460084944,"version":"build-2065373602"},"reference-count":94,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2U01AI096299-13"],"award-info":[{"award-number":["2U01AI096299-13"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"Center for Information Technology","doi-asserted-by":"publisher","award":["5U54CA254568-02"],"award-info":[{"award-number":["5U54CA254568-02"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,7,22]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cervical infections, high-grade abnormalities and cancer caused by the targeted HPV types. However, the evidence for their effectiveness in women living with HIV (WLWH) is less clear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>WLWH and HIV-negative women who likely did (birth cohorts 1996 and later) and WLWH and HIV(\u2212) negative who likely did not (birth cohorts before 1996) receive HPV vaccination (n=3028; 757 participants for each of the four groups). Between groups, we will compare cervicovaginal, anal and oral prevalent and 6\u201312 month persistent HPV6\/11\/16\/18 infections as measured using a modified AmpFire HPV genotyping assay that tests for 15 high-risk or intermediate-risk HPV genotypes, HPV6 and HPV11. We will also compare the HPV immune response in HPV-vaccinated WLWH to HPV-vaccinated HIV-negative women using an anti-HPV16 and anti-HPV18 ELISA. Vaccination status will be confirmed through national vaccination records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Analysis<\/jats:title>\n                  <jats:p>We will calculate point prevalence and prevalence of 6\u201312 month persisting infections by individual HPV-type specific infections and groups of infections for each anatomic site and for each group of women. Results will be stratified by age at vaccination, age at enrolment and the number of doses (3 vs 2) as well as other factors possibly associated with HPV prevalence. Differences in endpoints between groups, overall and between subgroups, will be tested for statistical significance (p&lt;0.05) using Fisher\u2019s exact or Pearson \u03c7<jats:sup>2<\/jats:sup> test. Differences in geometric mean titres and seropositivity will be tested for statistical significance using the Mann-Whitney and Fisher\u2019s exact tests, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The study was approved by the Albert Einstein College of Medicine Institutional Review Board and the Rwanda National Ethics Committee. Results will be disseminated through publication in peer-reviewed journals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061650","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T12:52:01Z","timestamp":1661431921000},"page":"e061650","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5522","authenticated-orcid":false,"given":"Gad","family":"Murenzi","sequence":"first","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Shumbusho","sequence":"additional","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Hansen","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanase","family":"Munyaneza","sequence":"additional","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia C","family":"Gage","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Muhoza","sequence":"additional","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustin","family":"Kanyabwisha","sequence":"additional","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Pierz","sequence":"additional","affiliation":[{"name":"Department of Community Health and Health Sciences, CUNY Graduate School of Public Health and Health Policy, New York, New York, USA"},{"name":"Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Tuyisenge","sequence":"additional","affiliation":[{"name":"Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda"},{"name":"Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-6405","authenticated-orcid":false,"given":"Kathryn","family":"Anastos","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA"},{"name":"Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-5985","authenticated-orcid":false,"given":"Philip E","family":"Castle","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA"},{"name":"Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"2025101811311089000_12.8.e061650.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"2025101811311089000_12.8.e061650.2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-4-8"},{"key":"2025101811311089000_12.8.e061650.3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp534"},{"key":"2025101811311089000_12.8.e061650.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"2025101811311089000_12.8.e061650.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.06.021"},{"key":"2025101811311089000_12.8.e061650.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70225-5"},{"key":"2025101811311089000_12.8.e061650.7","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-227"},{"key":"2025101811311089000_12.8.e061650.8","unstructured":"Australian Government Department of Health . Historical data from the National HPV vaccination program register. Available: https:\/\/www.health.gov.au\/resources\/collections\/historical-data-from-the-national-hpv-vaccination-program-register [Accessed 2 Jan 2022]."},{"key":"2025101811311089000_12.8.e061650.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70841-2"},{"key":"2025101811311089000_12.8.e061650.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1458"},{"key":"2025101811311089000_12.8.e061650.11","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.01038"},{"key":"2025101811311089000_12.8.e061650.12","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"2025101811311089000_12.8.e061650.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30468-1"},{"key":"2025101811311089000_12.8.e061650.14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt460"},{"key":"2025101811311089000_12.8.e061650.15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1968"},{"key":"2025101811311089000_12.8.e061650.16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix244"},{"key":"2025101811311089000_12.8.e061650.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit192"},{"key":"2025101811311089000_12.8.e061650.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"2025101811311089000_12.8.e061650.19","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"2025101811311089000_12.8.e061650.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338"},{"key":"2025101811311089000_12.8.e061650.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02178-4"},{"key":"2025101811311089000_12.8.e061650.22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025101811311089000_12.8.e061650.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500060023008"},{"key":"2025101811311089000_12.8.e061650.24","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"2025101811311089000_12.8.e061650.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61050-2"},{"key":"2025101811311089000_12.8.e061650.26","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2768"},{"key":"2025101811311089000_12.8.e061650.27","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025101811311089000_12.8.e061650.28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","article-title":"Anal cancer risk among people with HIV infection in the United States","volume":"36","author":"Col\u00f3n-L\u00f3pez","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025101811311089000_12.8.e061650.29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-03502-0_7","article-title":"HPV-associated anal cancer in the HIV\/AIDS patient","volume":"177","author":"Wang","year":"2019","journal-title":"Cancer Treat Res"},{"key":"2025101811311089000_12.8.e061650.30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/QAD.0000000000001765","article-title":"HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer","volume":"32","author":"Liu","year":"2018","journal-title":"AIDS"},{"key":"2025101811311089000_12.8.e061650.31","first-page":"505","article-title":"Cervical cancer prevention and control in women living with human immunodeficiency virus","volume":"71","author":"Castle","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025101811311089000_12.8.e061650.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2019.100174","article-title":"HPV vaccination in HIV infection","volume":"8","author":"Lacey","year":"2019","journal-title":"Papillomavirus Res"},{"key":"2025101811311089000_12.8.e061650.33","doi-asserted-by":"publisher","DOI":"10.1086\/656320"},{"key":"2025101811311089000_12.8.e061650.34","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2014.08.011","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults","volume":"32","author":"Giacomet","year":"2014","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.35","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.vaccine.2017.02.021","article-title":"Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine","volume":"35","author":"Levin","year":"2017","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0000000000001773","article-title":"Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children","volume":"32","author":"Weinberg","year":"2018","journal-title":"AIDS"},{"key":"2025101811311089000_12.8.e061650.37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/cid\/ciy1040","article-title":"Human papillomavirus antibody levels and quadrivalent vaccine clinical effectiveness in perinatally human immunodeficiency virus-infected and exposed, uninfected youth","volume":"69","author":"Moscicki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025101811311089000_12.8.e061650.38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit319"},{"key":"2025101811311089000_12.8.e061650.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu238"},{"key":"2025101811311089000_12.8.e061650.40","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2025101811311089000_12.8.e061650.42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000000745","article-title":"High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298","volume":"45","author":"Cranston","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2025101811311089000_12.8.e061650.43","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS clinical trials group protocol A5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025101811311089000_12.8.e061650.44","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025101811311089000_12.8.e061650.45","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025101811311089000_12.8.e061650.46","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.097253"},{"key":"2025101811311089000_12.8.e061650.47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177773"},{"key":"2025101811311089000_12.8.e061650.48","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1539-6"},{"key":"2025101811311089000_12.8.e061650.49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.12186","article-title":"Progress in HPV vaccination in low- and lower-middle-income countries","volume":"138","author":"LaMontagne","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"2025101811311089000_12.8.e061650.50","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6030061","article-title":"Prevention of cervical cancer in sub-Saharan Africa: the advantages and challenges of HPV vaccination","volume":"6","author":"Black","year":"2018","journal-title":"Vaccines"},{"key":"2025101811311089000_12.8.e061650.51","unstructured":"Rwanda population-based HIV impact assessment October 2019."},{"key":"2025101811311089000_12.8.e061650.52","unstructured":"The World Bank . Rwanda, 2022."},{"key":"2025101811311089000_12.8.e061650.53","unstructured":"Rwanda Ministry of Health . National guidelines for prevention and management of HIV, STIs & other blood borne infections, 2013."},{"key":"2025101811311089000_12.8.e061650.54","unstructured":"Rwanda Ministry of Health . Circular of key changes in HIV prevention and management guidelines, 2018."},{"key":"2025101811311089000_12.8.e061650.55","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(15)70075-6","article-title":"Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging","volume":"16","author":"Lowy","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025101811311089000_12.8.e061650.56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/LGT.0000000000000334","article-title":"ASCCP colposcopy standards: Risk-Based colposcopy practice","volume":"21","author":"Wentzensen","year":"2017","journal-title":"J Low Genit Tract Dis"},{"key":"2025101811311089000_12.8.e061650.57","unstructured":"World Health Organization . WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/96735\/WHO_RHR_13.21_eng.pdf"},{"key":"2025101811311089000_12.8.e061650.58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijgo.2015.07.038","article-title":"World Health organization guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer","volume":"132","author":"Santesso","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"key":"2025101811311089000_12.8.e061650.59","unstructured":"World Health Organization . WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva, Switzerland, 2019."},{"key":"2025101811311089000_12.8.e061650.60","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000525"},{"key":"2025101811311089000_12.8.e061650.61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k499"},{"key":"2025101811311089000_12.8.e061650.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3633"},{"key":"2025101811311089000_12.8.e061650.63","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025101811311089000_12.8.e061650.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4823"},{"key":"2025101811311089000_12.8.e061650.65","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2014.08.004","article-title":"Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18","volume":"32","author":"Brown","year":"2014","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.66","doi-asserted-by":"crossref","DOI":"10.1186\/s13027-021-00355-6","article-title":"Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV","volume":"16","author":"Murenzi","year":"2021","journal-title":"Infect Agent Cancer"},{"key":"2025101811311089000_12.8.e061650.67","doi-asserted-by":"crossref","DOI":"10.1186\/s13027-020-00328-1","article-title":"Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening","volume":"15","author":"Zhang","year":"2020","journal-title":"Infect Agent Cancer"},{"key":"2025101811311089000_12.8.e061650.68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jmoldx.2019.12.004","article-title":"An isothermal, multiplex amplification assay for detection and genotyping of human papillomaviruses in formalin-fixed, paraffin-embedded tissues","volume":"22","author":"Tang","year":"2020","journal-title":"J Mol Diagn"},{"key":"2025101811311089000_12.8.e061650.69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002376","article-title":"Anogenital human papillomavirus and HIV infection in Rwandan men who have sex with men","volume":"84","author":"Murenzi","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025101811311089000_12.8.e061650.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.074"},{"key":"2025101811311089000_12.8.e061650.71","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.4161\/hv.34408","article-title":"Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus","volume":"10","author":"Herrin","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2025101811311089000_12.8.e061650.72","unstructured":"HPV Serology Laboratory . HPV serology laboratory standard operating procedure. Available: https:\/\/frederick.cancer.gov\/sites\/default\/files\/2021-06\/HSL%20LAB%20007%20HPV%20Antibody%20ELISA.pdf"},{"key":"2025101811311089000_12.8.e061650.73","unstructured":"National Institute for Biological Standards and Control . WHO international standard 05-134 HPV 16 antibodies. Available: https:\/\/www.nibsc.org\/documents\/ifu\/05-134.pdf"},{"key":"2025101811311089000_12.8.e061650.74","unstructured":"National Institute for Biological Standards and Control . WHO international standard 1st who international standard for anti-human papillomavirus 18 serum. Available: https:\/\/www.nibsc.org\/documents\/ifu\/10-140.pdf"},{"key":"2025101811311089000_12.8.e061650.75","unstructured":"World Health Organization . In vitro diagnostics and laboratory technology: ELISA tests. Available: https:\/\/www.who.int\/diagnostics_laboratory\/faq\/elisa\/en\/"},{"key":"2025101811311089000_12.8.e061650.76","unstructured":"American Society for Clinical Pathology . Partners for cancer diagnosis and treatment in Africa: new telepathology system to serve all hospitals in Kigali, Rwanda. Available: https:\/\/www.ascp.org\/content\/docs\/default-source\/get-involved-pdfs\/partners-in-cancer-diagnosis-newsletter\/partners-newsletter-july-2017.pdf?sfvrsn=2"},{"key":"2025101811311089000_12.8.e061650.77","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2014.07.014","article-title":"Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes","volume":"32","author":"Barzon","year":"2014","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.78","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.vaccine.2019.03.052","article-title":"Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"37","author":"Godi","year":"2019","journal-title":"Vaccine"},{"key":"2025101811311089000_12.8.e061650.79","doi-asserted-by":"publisher","DOI":"10.1086\/428779"},{"key":"2025101811311089000_12.8.e061650.80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jiaa065","article-title":"Twelve-year trend in the prevalence of high-risk human papillomavirus infection among Rwandan women living with HIV","volume":"222","author":"Murenzi","year":"2020","journal-title":"J Infect Dis"},{"key":"2025101811311089000_12.8.e061650.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2008.07.009"},{"key":"2025101811311089000_12.8.e061650.82","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"2025101811311089000_12.8.e061650.83","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-225","article-title":"Sexual risk behaviors among youth heads of household in Gikongoro, South Province of Rwanda","volume":"12","author":"Ntaganira","year":"2012","journal-title":"BMC Public Health"},{"key":"2025101811311089000_12.8.e061650.84","unstructured":"Umutesi J . Early sexual debut and subsequent risk factors among youth in Rwanda: a secondary data analysis of Rwanda demographic and health survey 2015. Kigali, Rwanda: University of Rwanda, 2016."},{"key":"2025101811311089000_12.8.e061650.85","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn044"},{"key":"2025101811311089000_12.8.e061650.86","doi-asserted-by":"publisher","DOI":"10.1086\/516784"},{"key":"2025101811311089000_12.8.e061650.87","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.10.9518"},{"key":"2025101811311089000_12.8.e061650.88","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.12.18281"},{"key":"2025101811311089000_12.8.e061650.89","unstructured":"Government of Rwanda . Rwanda population-based HIV impact assessment (RPHIA): 2018\u20132019. Rwanda, 2019."},{"key":"2025101811311089000_12.8.e061650.90","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries","volume":"8","author":"Han","year":"2021","journal-title":"Lancet HIV"},{"key":"2025101811311089000_12.8.e061650.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025101811311089000_12.8.e061650.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025101811311089000_12.8.e061650.93","unstructured":"REDCap , 2021. Available: https:\/\/www.project-redcap.org\/ [Accessed 29 Dec 2021]."},{"key":"2025101811311089000_12.8.e061650.94","unstructured":"National Institutes of Health . NIH reporter: building research capacity to address the challenge of non communicable diseases and injuries in Rwanda the GUKORANA research center. Available: https:\/\/reporter.nih.gov\/search\/h81sRNzkn0e71v5Y6Xo2WQ\/project-details\/9854425"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:31:24Z","timestamp":1760812284000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":94,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,25]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bmjopen-2022-061650"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061650","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}